Hi msowid. The pre operational pharmacies were the one in Kansas and one in upstate NY. The Veneto ones were open for business. Generex was even gearing to sell cbd water in their own pharmacies.
“We have acquired an outstanding management team that has built this business from the ground up to achieve unaudited revenues of more than $66 million over the past 12 months through this first set of Veneto assets, whilst operating in only three states.”
“The first tranche of the Acquisition closed on October 3, 2018 (the “First Closing Date”). On the Closing Date, NuGenerex purchased the operating assets of eight pharmacies, a wholesale pharmacy purchasing company, and an in-network laboratory (the “First Closing Assets”).”
https://www.businesswire.com/news/home/201810...ing-Assets
Veneto rev over the 12 months of their last fiscal year were $73.6 mill. So according to Joe in the Gnbt press release, the Pharmacies, a wholesale pharmacy purchasing company, and a lab earned nearly all of the Veneto rev. Did the MSO model do the remaining $5.6 mil for that year? Did any of the now closed pharmacies earn rev in the Gnbt quarterly that won’t reoccur? So, in my opinion, Generex needs to help shareholders understand what exactly is Veneto and are any assets from the first tranche operational? I know that Generex can have more product to sell thru their MSO after further acquisitions of Fuse, Pantheon and Medi, is Veneto already selling their products without owning them?
Not being negative- just asking questions based on the filings and press releases. I understand using the pooled shares is advantageous to current shareholders for any acquisition. We still need to understand them since whether they’re ultimately successful or not directly impacts the value of our shares. Jmho
“We have acquired an outstanding management team that has built this business from the ground up to achieve unaudited revenues of more than $66 million over the past 12 months through this first set of Veneto assets, whilst operating in only three states.”
“The first tranche of the Acquisition closed on October 3, 2018 (the “First Closing Date”). On the Closing Date, NuGenerex purchased the operating assets of eight pharmacies, a wholesale pharmacy purchasing company, and an in-network laboratory (the “First Closing Assets”).”
https://www.businesswire.com/news/home/201810...ing-Assets
Veneto rev over the 12 months of their last fiscal year were $73.6 mill. So according to Joe in the Gnbt press release, the Pharmacies, a wholesale pharmacy purchasing company, and a lab earned nearly all of the Veneto rev. Did the MSO model do the remaining $5.6 mil for that year? Did any of the now closed pharmacies earn rev in the Gnbt quarterly that won’t reoccur? So, in my opinion, Generex needs to help shareholders understand what exactly is Veneto and are any assets from the first tranche operational? I know that Generex can have more product to sell thru their MSO after further acquisitions of Fuse, Pantheon and Medi, is Veneto already selling their products without owning them?
Not being negative- just asking questions based on the filings and press releases. I understand using the pooled shares is advantageous to current shareholders for any acquisition. We still need to understand them since whether they’re ultimately successful or not directly impacts the value of our shares. Jmho
